ESMO Gastrointestinal Oncology最新文献

{"title":"Anti-EGFR re-challenge with chemotherapy in RAS wild-type advanced colorectal cancer (A-REPEAT study): efficacy and correlations with tissue and plasma genotyping","authors":"J. Sgouros ,&nbsp;A. Eliades ,&nbsp;K. Papadopoulou ,&nbsp;N. Korfiatis ,&nbsp;D. Papamichael ,&nbsp;E. Fountzilas ,&nbsp;E. Tsolaki ,&nbsp;A. Achilleos ,&nbsp;K. Tsangaras ,&nbsp;C. Loizides ,&nbsp;G. Oikonomopoulos ,&nbsp;T. Makatsoris ,&nbsp;E. Kypri ,&nbsp;M. Ioannides ,&nbsp;G. Koumbaris ,&nbsp;G. Fountzilas ,&nbsp;P.C. Patsalis ,&nbsp;G. Pentheroudakis","doi":"10.1016/j.esmogo.2024.100120","DOIUrl":"10.1016/j.esmogo.2024.100120","url":null,"abstract":"<div><h3>Background</h3><div>Approved treatments for colorectal cancer (CRC) patients pretreated with two lines of therapy are of limited efficacy. Anti-epidermal growth factor receptor (EGFR) re-challenge might represent an option in RAS wild-type tumours. This study aimed to evaluate the efficacy of anti-EGFR re-challenge strategies (panitumumab/chemotherapy).</div></div><div><h3>Materials and methods</h3><div>RAS wild-type metastatic CRC patients following first-line chemotherapy + anti-EGFR agent and second-line chemotherapy ± anti-vascular endothelial growth factor agent were eligible. Panitumumab with irinotecan or oxaliplatin-based chemotherapy was used. The primary objective was response rate (RR). Secondary objectives were safety, progression-free survival and overall survival. Next-generation sequencing-based genotyping in archived tissue and plasma was carried out to identify prognostic factors.</div></div><div><h3>Results</h3><div>The study closed prematurely, due to poor accrual, with 23 patients included. Most patients had primary tumours in the left colon/rectum, and the liver was the most common metastatic site. Treatment modifications were required in 74% of patients due to side-effects primarily, neutropenia and acneiform rash. One patient died from hepatic failure. The objective RR in the intention-to-treat population was 13%, and the disease control rate (DCR) was 52%. Forty-eight percent of patients tested via liquid biopsy had <em>RAS</em> mutations before re-challenge with panitumumab despite a median interval from previous anti-EGFR therapy of 12 months. Control of disease did not correlate with the results of liquid biopsy. RR and DCR in patients without <em>RAS</em> mutations in liquid biopsies were 18.2% and 54.5%, respectively.</div></div><div><h3>Conclusion</h3><div>Panitumumab/chemotherapy as an anti-EGFR re-challenge strategy had modest activity in our patient cohort.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"7 ","pages":"Article 100120"},"PeriodicalIF":0.0,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143159963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What is the role of physical exercise after surgery for gastric cancer? A scoping review","authors":"M. Monticone ,&nbsp;B. Rocca ,&nbsp;A. Pretta ,&nbsp;A. Scribante ,&nbsp;M. Scartozzi ,&nbsp;F. Del Farra","doi":"10.1016/j.esmogo.2024.100117","DOIUrl":"10.1016/j.esmogo.2024.100117","url":null,"abstract":"<div><div>The overall role of physical exercise (PE) in addressing the disabling effects of gastric cancer (GC) after surgery remains uncertain. This scoping review (ScR) aims to systematically collect, map, and present the current evidence on studies reporting data on PE in individuals with GC. This ScR followed the 2020 recommendations of the <em>Joanna Briggs Institute Methodological Guidance</em> and adhered to the <em>Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Scoping Reviews</em>. A comprehensive search was conducted in PubMed, Scopus, and the Cochrane Central Register of Controlled Trials (CENTRAL) up to January 2024. Original studies were identified, and findings were presented both numerically and thematically. Out of 1115 articles initially identified, 9 studies met the inclusion criteria. The number of publications on this topic has increased over time, with most studies conducted in Western countries. Of the included studies, 6 (66.7%) were primary research articles, while 3 (33.3%) were systematic reviews. The overall sample size comprised 226 individuals, with a mean age of 61 ± 5.3 years. The studies consistently reported a positive impact of PE in both inpatient and outpatient settings. However, significant heterogeneity was observed in the types and characteristics of PE, outcome measures, and reference populations. Physiotherapists were the primary healthcare professionals involved in delivering care. This review highlights the need for further high-quality studies dedicated to investigating the role of PE after surgery for GC. In addition, multidisciplinary rehabilitation is recommended to address the complex needs of this patient population.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"7 ","pages":"Article 100117"},"PeriodicalIF":0.0,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143159538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Managing zolbetuximab-induced nausea and vomiting: a proposal for a pragmatic approach in clinical practice","authors":"K. Shimozaki ,&nbsp;A. Ooki ,&nbsp;Y. Yamahata ,&nbsp;T. Aoyama ,&nbsp;K. Yoshino ,&nbsp;M. Tamba ,&nbsp;S. Udagawa ,&nbsp;S. Fukuoka ,&nbsp;H. Osumi ,&nbsp;T. Wakatsuki ,&nbsp;E. Shinozaki ,&nbsp;M. Ogura ,&nbsp;K. Chin ,&nbsp;K. Yamaguchi","doi":"10.1016/j.esmogo.2024.100128","DOIUrl":"10.1016/j.esmogo.2024.100128","url":null,"abstract":"<div><h3>Background</h3><div>The global phase III SPOTLIGHT and GLOW trials confirmed the superiority of zolbetuximab plus chemotherapy over chemotherapy alone for claudin 18.2-positive advanced gastric cancer (AGC). However, severe nausea/vomiting during zolbetuximab infusion remains a significant safety concern. Our study aimed to evaluate the safety management strategy’s applicability in our institution.</div></div><div><h3>Patients and methods</h3><div>This registry-based observational study assessed the combination of fosnetupitant, dexamethasone, and 5-HT₃-receptor antagonist in patients receiving zolbetuximab plus chemotherapy. The initial zolbetuximab infusion rate was set at 75 ml/h for the first 60 min, and then 250 ml/h thereafter. The primary endpoint was the feasibility of our management and vomiting prevention during cycle 1.</div></div><div><h3>Results</h3><div>Among 21 patients (median age 61 years; male 48%; diffuse-type histology 81%; prior gastrectomy 38%; peritoneal metastases 57%), the incidence of nausea/vomiting during zolbetuximab initiation in cycle 1 was 62%/9.5%, with a 62% infusion interruption rate. The median time to first nausea was 93 min (range 77-127 min); median interruption time was 40 min (16-68 min); and median total infusion time of zolbetuximab was 257 min (154-343 min). All patients successfully completed zolbetuximab administration in cycle 1, with an 81% vomiting prevention rate. At cycle 2 day 1, 3 of 14 patients (21%) experienced nausea, with no vomiting.</div></div><div><h3>Conclusion</h3><div>First-line zolbetuximab plus chemotherapy was safely introduced to real-world patients with claudin 18.2-positive AGC, with effective management of nausea and vomiting, applicable in clinical practice.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"7 ","pages":"Article 100128"},"PeriodicalIF":0.0,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143159959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"German guidelines for the diagnosis and treatment of squamous-cell carcinoma and adenocarcinoma of the esophagus—version 4.0","authors":"M.P. Ebert ,&nbsp;W. Fischbach ,&nbsp;S. Hollerbach ,&nbsp;J. Höppner ,&nbsp;D. Lorenz ,&nbsp;M. Stahl ,&nbsp;M. Stuschke ,&nbsp;O. Pech ,&nbsp;U. Vanhoefer ,&nbsp;C. Bruns ,&nbsp;C. Ell ,&nbsp;M. Follmann ,&nbsp;U. Goerling ,&nbsp;L. Grenacher ,&nbsp;J. Haardt ,&nbsp;A.H. Hölscher ,&nbsp;R. Hummel ,&nbsp;W.T. Knoefel ,&nbsp;J. Körber ,&nbsp;R. Langer ,&nbsp;R. Porschen","doi":"10.1016/j.esmogo.2024.100112","DOIUrl":"10.1016/j.esmogo.2024.100112","url":null,"abstract":"<div><div>This guideline for the diagnosis and treatment of squamous-cell carcinoma and adenocarcinoma of the esophagus was developed and managed by the German Guideline Program in Oncology (GGPO) of the Association of the Scientific Medical Societies in Germany (AWMF), German Cancer Society (DKG), and German Cancer Aid (DKH). The guideline commission comprised multidisciplinary experts from various professional associations and organizations involved in the management of esophageal cancer, as well as a patient representative. Quality of the evidence is presented using Oxford evidence-based medicine system, and recommendations were graded in a formal consensus process using a recommendation grading scheme.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"7 ","pages":"Article 100112"},"PeriodicalIF":0.0,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143159964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eligibility and workload implications of adjuvant immunotherapy in patients with resected esophageal and gastroesophageal junction (ESO/GEJ) cancer","authors":"T.H. Lee ,&nbsp;S. Gill","doi":"10.1016/j.esmogo.2024.100115","DOIUrl":"10.1016/j.esmogo.2024.100115","url":null,"abstract":"<div><h3>Background</h3><div>The CheckMate (CM) 577 trial demonstrated the efficacy of 12 months of adjuvant nivolumab for esophageal (ESO)/gastroesophageal junction (GEJ) cancer patients with residual pathological disease after neoadjuvant chemoradiation. Nivolumab is now an approved and funded regimen in British Columbia (BC). This retrospective study examines its real-world eligibility and resource implications.</div></div><div><h3>Materials and methods</h3><div>We conducted an ethics board-approved chart review of patients who underwent <em>CROSS</em> chemoradiation at BC Cancer from January 2016 to December 2020. Patient eligibility was determined per CM577 and <em>GIAJNIV</em> criteria. We assessed the resource impact of nivolumab by projecting the number of MD and chemotherapy visits, and anticipated G3/4 toxicity events per the CM577 trial.</div></div><div><h3>Results</h3><div>We identified 677 patients (63% ESO and 37% GEJ; 74% adenocarcinomas and 25% squamous cell carcinomas). Among the 460 who had resection, 79% had residual pathological disease. 68% (<em>n</em> = 249) and 88% (<em>n</em> = 321) were eligible for adjuvant nivolumab per CM577 and <em>GIAJNIV</em> criteria, respectively. In BC, this equates to ∼60 patients/year, resulting in 768 additional chemotherapy and potentially an equal number of MD visits, totaling 256 MD workhours annually. With a 34% G3/4 toxicity rate, an estimated 20 patients/year may require medical intervention.</div></div><div><h3>Conclusions</h3><div>Adjuvant nivolumab is an important treatment option for resected ESO/GEJ cancer patients. Our findings suggest that a substantial portion (88%) of those with residual pathological disease would be eligible for 12 months of therapy. In addition to treatments costs, the implementation of new therapy indications should consider the additional workload impact on oncologists.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"7 ","pages":"Article 100115"},"PeriodicalIF":0.0,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143160897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maintenance chemotherapy in biliary tract tumours in the era of immuno-chemotherapy","authors":"A. Lamarca ,&nbsp;J. Adeva ,&nbsp;I. Ales Díaz ,&nbsp;R. Alvarez Gallego ,&nbsp;A.J. Muñoz Martín ,&nbsp;T. Macarulla Mercade","doi":"10.1016/j.esmogo.2024.100116","DOIUrl":"10.1016/j.esmogo.2024.100116","url":null,"abstract":"<div><div>Biliary tract tumours (BTCs) are malignancies with a poor prognosis. Regarding first-line therapy options, cisplatin and gemcitabine (CisGem) alone has been the standard therapy option for more than a decade. This has changed recently, due to the incorporation of immunotherapy into this combo, with latest studies showing how the addition of immunotherapy with either durvalumab or pembrolizumab can improve patients’ outcomes. However, the adequate duration of CisGem in advanced BTCs has remained an open debate. We provide a detailed summary and discussion on current evidence in terms of adequate duration of chemotherapy in the immuno-chemotherapy era, with the aim of informing best practice. Based on the data available and summarised here, the differences are small and individual decisions should be pursued for the sake of not compromising the bone marrow reserve for delivering second-line therapies. In the era of immuno-chemotherapy, maintenance chemotherapy seems to be of very limited benefit and maintenance with the checkpoint inhibitors being utilised seems sufficient. For patients being treated with chemotherapy alone, maintenance chemotherapy should also be carefully considered and decisions individualised.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"7 ","pages":"Article 100116"},"PeriodicalIF":0.0,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143160880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concomitant proton pump inhibitors and capecitabine-based chemoradiotherapy in rectal cancer: an ancillary study from the PRODIGE 23 trial","authors":"M. Bridoux ,&nbsp;E. Aymes ,&nbsp;T. Conroy ,&nbsp;S. Gourgou ,&nbsp;A. Carnot ,&nbsp;C. Borg ,&nbsp;M.-C. Le Deley ,&nbsp;A. Turpin","doi":"10.1016/j.esmogo.2024.100119","DOIUrl":"10.1016/j.esmogo.2024.100119","url":null,"abstract":"<div><h3>Background</h3><div>Approximately one in five cancer patients use proton pump inhibitors (PPIs). In this work, we studied the effect of PPI co-medication during neoadjuvant chemoradiotherapy (NCRT) for locally advanced rectal cancer (LARC) based on the phase III PRODIGE 23 trial.</div></div><div><h3>Materials and methods</h3><div>We gathered data on PPI exposure for patients from the PRODIGE 23 trial. PPI exposure was defined as PPI use during capecitabine treatment, either during CRT or as adjuvant therapy. The oncological outcomes included recurrence-free survival (RFS), overall survival (OS), cumulative incidence of metastatic recurrence, and pathological response to preoperative treatment. The association of PPI use with RFS, metastatic recurrence, and histological complete response was evaluated using univariate and multivariate Cox models.</div></div><div><h3>Results</h3><div>We analyzed data from 332 patients [165 in the NAC group with mFOLFIRINOX, capecitabine-based (CAP50) CRT, and surgery, and 167 in the standard-of-care control arm with CAP50 CRT and surgery]. Thirty-eight patients were co-administered a PPI during capecitabine administration. After a median follow-up of 49.4 months, the 3-year RFS rates were 74.1% [95% confidence interval (CI) 68.6% to 78.8%] and 68.4% (95% CI 51.2% to 80.7%) in the non-PPI and PPI groups, respectively, with no significant differences (<em>P</em> = 0.16). The 3-year OS rates were 91.2% (95% CI 87.2% to 93.9%) and 83% (95% CI 65.7% to 92%) in the non-PPI group and PPI groups, respectively, with no significant differences (<em>P</em> = 0.38). We observed no difference in the pathological complete response rate between both groups.</div></div><div><h3>Conclusions</h3><div>We observed no significant association between PPI exposure and survival or pathological response of patients receiving capecitabine-based CRT for LARC, supporting earlier research findings.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"7 ","pages":"Article 100119"},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143160881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PD-L1 expression as a negative predictive biomarker in advanced esophageal squamous-cell cancer treated with chemotherapy alone","authors":"M. Sachdeva ,&nbsp;J.J. Zhao ,&nbsp;K.X. Zhu ,&nbsp;D.T.W. Yap ,&nbsp;N.Z.H. Wong ,&nbsp;N.B. Kumarakulasinghe ,&nbsp;J. Tey ,&nbsp;R. Sundar","doi":"10.1016/j.esmogo.2024.100109","DOIUrl":"10.1016/j.esmogo.2024.100109","url":null,"abstract":"<div><h3>Background</h3><div>Programmed death-ligand 1 (PD-L1) expression is a well-established positive predictive biomarker for response to immunotherapy in advanced esophageal squamous-cell carcinoma (aESCC). However, the association between PD-L1 and response to chemotherapy alone remains unclear. This study aims to determine the prognostic significance of PD-L1 expression in patients treated with first-line chemotherapy alone in aESCC.</div></div><div><h3>Materials and methods</h3><div>First-line phase III randomized trials that included PD-L1 expression as a biomarker in aESCC were extracted after a systematic search. A graphical reconstructive algorithm was used to estimate time-to-event outcomes from reported Kaplan–Meier (KM) plots and, where unavailable, KMSubtraction was utilized to derive KM plots of unreported PD-L1 subgroups. Thereafter, an individual patient data meta-analysis was conducted. Survival analyses for overall survival (OS) and progression-free survival (PFS) were conducted with Cox proportional hazards models with a shared-frailty term incorporated to account for interstudy differences.</div></div><div><h3>Results</h3><div>Chemotherapy arms from five randomized phase III trials—CheckMate-648, ESCORT-1st, KEYNOTE-590, RATIONALE-306 and ORIENT-15—comprising 1517 patients were included in the OS analysis. Compared with PD-L1-low-expressing tumors, patients with PD-L1-high-expressing tumors were at a significantly higher risk of mortality [hazard ratio (HR) 1.153, 95% confidence interval (CI) 1.018-1.305, <em>P</em> = 0.025]. Three trials—CheckMate-648, ESCORT-1st and ORIENT-15—comprising 949 patients treated with chemotherapy alone were included in the PFS analysis. Patients with PD-L1-high-expressing tumors had a non-significant increased risk of tumor progression (HR 1.076, 95% CI 0.923 –1.253, <em>P</em> = 0.349).</div></div><div><h3>Conclusions</h3><div>Our study found PD-L1 expression is a negative predictor of OS in aESCC treated with first-line chemotherapy.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"7 ","pages":"Article 100109"},"PeriodicalIF":0.0,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143159539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-cell RNA sequencing via endoscopic ultrasound-guided fine-needle biopsy for pancreatic tumors uncovered an aggressive subclone with a poor prognosis","authors":"Y.-Y. Su ,&nbsp;M.-Y. Lin ,&nbsp;S.M. Cheng ,&nbsp;W.-L. Chang ,&nbsp;C.-W. Hsu ,&nbsp;C.-M. Yeh ,&nbsp;C.-C. Yu ,&nbsp;Y.-C. Hou ,&nbsp;C.-J. Huang ,&nbsp;Y.-S. Liu ,&nbsp;Y.-J. Chao ,&nbsp;D.-Y. Hwang ,&nbsp;Y.S. Shan ,&nbsp;L.-T. Chen","doi":"10.1016/j.esmogo.2024.100113","DOIUrl":"10.1016/j.esmogo.2024.100113","url":null,"abstract":"<div><h3>Background</h3><div>Single-cell RNA sequencing (scRNA-seq) is a powerful tool which can unveil regulatory connections between genes and cells. However, due to the high demand for tissue quality, most scRNA-seq for pancreatic cancer is carried out by surgical specimen. This study (NCT05767697) aims to gain practical experience in carrying out scRNA-seq using endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB).</div></div><div><h3>Materials and methods</h3><div>With a within-subjects design, two punctures from the same lesion, with a negative pressure of 5 ml (suction group) and without applying suction (non-suction group), were evaluated. Each biopsy sample was separated into three parts: white tissue, red material, and buffer for living cell counting. scRNA-seq was carried out according to the manufacturer’s protocol. The pancreatic adenocarcinoma dataset in The Cancer Genome Atlas (TCGA) was used as external validation.</div></div><div><h3>Results</h3><div>A total of 20 patients with 40 specimens were enrolled. The suction group achieved a success rate of 80% (16/20), which was significantly higher than the 10% (2/20) success rate in the non-suction group (<em>P</em> &lt; 0.001). scRNA-seq data were generated for four patients, including two early stage and two late stage. Overall, 15 major cell subtypes, including 4 cancer subclones, were identified across early and late stages. Analysis of differentially expressed genes identified an aggressive subclone highlighted by ubiquitin-conjugating enzyme E2 C (UBE2C) high expression, commonly in late stage. The TCGA dataset also demonstrated that UBE2C high-expression pancreatic cancer had a poor prognosis.</div></div><div><h3>Conclusions</h3><div>EUS-FNB with a negative pressure of 5 ml is feasible for scRNA-seq in clinical practice. A UBE2C high-expression subclone correlates with a poor prognosis, potentially becoming a new therapeutic target in future studies.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"7 ","pages":"Article 100113"},"PeriodicalIF":0.0,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143160896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating trastuzumab deruxtecan in patients with gastrooesophageal adenocarcinoma who are ctDNA and HER2 positive: DECIPHER","authors":"E. Smyth ,&nbsp;D. Griffiths ,&nbsp;K. Cozens ,&nbsp;S. Ewings ,&nbsp;R. Waugh ,&nbsp;R.C. Turkington ,&nbsp;K. Foley ,&nbsp;R. Roy ,&nbsp;S. Ngan ,&nbsp;R. Owen ,&nbsp;D. Chuter ,&nbsp;C. Steele ,&nbsp;G. Griffiths","doi":"10.1016/j.esmogo.2024.100114","DOIUrl":"10.1016/j.esmogo.2024.100114","url":null,"abstract":"<div><div>Operable gastrooesophageal adenocarcinoma (GOA) is treated with multimodality therapy which is curative in &lt;50% of patients. Patients in the UK with operable GOA are treated with chemotherapy before and following surgery. Patients who have circulating tumour DNA (ctDNA) present after surgery have worse survival than ctDNA-negative patients. Trastuzumab deruxtecan (T-DXd), a novel human epidermal growth factor receptor 2 (HER2)-targeting antibody–drug conjugate is an effective drug in multiple tumour types and has been licensed to treat advanced HER2-positive GOA that has progressed after chemotherapy and trastuzumab and is European Society for Medical Oncology (ESMO) Guideline recommended. Evaluation of T-DXd in operable but micrometastatic GOA is an attractive option. DECIPHER is a multicentre, phase II trial testing the efficacy of T-DXd in reducing micrometastatic disease burden in HER2-positive GOA patients who are ctDNA positive after neoadjuvant chemotherapy and surgery. Patients will have their resection specimen and plasma analysed to confirm HER2 and ctDNA status post-operatively. Twenty-five ctDNA- and HER2-positive patients will be treated with 6.4 mg/kg T-DXd intravenously every 21 days for a maximum of eight cycles. Study follow-up visits will take place for a maximum of 2 years after treatment, with survival follow-up until the end of the study.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"6 ","pages":"Article 100114"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142747109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}